SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-061566
Filing Date
2023-11-09
Accepted
2023-11-09 08:31:08
Documents
79
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q cadl-20230930.htm   iXBRL 10-Q 2790285
2 EX-31.1 cadl-ex31_1.htm EX-31.1 17087
3 EX-31.2 cadl-ex31_2.htm EX-31.2 16817
4 EX-32.1 cadl-ex32_1.htm EX-32.1 9278
5 EX-32.2 cadl-ex32_2.htm EX-32.2 9714
  Complete submission text file 0000950170-23-061566.txt   9393030

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cadl-20230930_def.xml EX-101.DEF 298959
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cadl-20230930.xsd EX-101.SCH 69756
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cadl-20230930_pre.xml EX-101.PRE 425016
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT cadl-20230930_cal.xml EX-101.CAL 43371
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cadl-20230930_lab.xml EX-101.LAB 546809
73 EXTRACTED XBRL INSTANCE DOCUMENT cadl-20230930_htm.xml XML 1360367
Mailing Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494
Business Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494 617-916-5445
Candel Therapeutics, Inc. (Filer) CIK: 0001841387 (see all company filings)

IRS No.: 522214851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40629 | Film No.: 231390216
SIC: 2836 Biological Products, (No Diagnostic Substances)